The 3 Best Stocks to Buy for Summer 2021_老虎社区_美港股上老虎

The 3 Best Stocks to Buy for Summer 2021

Motley Fool2021-06-03

Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

IchiGo
·2021-06-04
BHC ever more than $100 few years back!
回复
1
举报
Slee49
·2021-06-04
Wow
回复
点赞
举报
peterongwk
·2021-06-03
[Miser] [Surprised]
回复
3
举报
收起
- peterongwk:
  Up
  2021-06-03
  回复
  举报
- RC_ADRIC:
  Nice
  2021-06-04
  回复
  举报
AHang
·2021-06-03
Gd
回复
点赞
举报
Anneater
·2021-06-03
Pls like and comment thanks
回复
1
举报
收起
- Anneater:
  Oh
  2021-06-03
  回复
  举报
RajaV
·2021-06-03
Nice
回复
点赞
举报
TomTam
·2021-06-03
Like and comment pls
回复
1
举报
收起
- Anneater:
  Ok
  2021-06-03
  回复
  举报
liwai100
·2021-06-03
Follow
回复
点赞
举报
Flyinng
·2021-06-03
Ok
回复
2
举报
收起
- WeiKeong:
  Like
  2021-06-03
  回复
  举报
Nairda
·2021-06-03
Like
回复
1
举报
收起
- WeiKeong:
  Like
  2021-06-03
  回复
  举报
DragonKC
·2021-06-03
Going shopping for bargain stock.
回复
点赞
举报
Alice156
·2021-06-03
Please like and comments
回复
2
举报
收起
- Jittertude:
  pls like my comment too. Thanks
  2021-06-03
  回复
  举报
Ultraviolet
·2021-06-03
Like and comment
回复
1
举报
Natdns
·2021-06-03
Good
回复
点赞
举报
收起
- Ultraviolet:
  Like and comment
  2021-06-03
  回复
  举报
Khoogl
·2021-06-03
Like
回复
点赞
举报
LongZR
·2021-06-03
Like and comment
回复
3
举报
收起
- LongZR:
  like and like
  2021-06-03
  回复
  举报
labide
·2021-06-03
[微笑]
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2140476423?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-06-03 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2140476423","market":"us","top_or_hot":-1,"title":"The 3 Best Stocks to Buy for Summer 2021","media":"Motley Fool","content":"<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BYND","symbol_name":"Beyond Meat, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","article_id":"2140476423","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","pubTimestamp":1622727648,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Looking for huge winners over the long run? Here are three top picks.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BYND":"Beyond Meat, Inc.","BMBL":"Bumble Inc.","BHC":"Bausch Health Companies Inc"},"translate_title":"2021年夏季最值得购买的3只股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHC":0.9,"BMBL":0.9,"BYND":0.9},"content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":118763550,"gmtCreate":1622762647170,"gmtModify":1634098363369,"author":{"id":"3571108991612603","authorId":"3571108991612603","name":"IchiGo","avatar":"https://static.tigerbbs.com/c7799d84b640de8d882c175fa85737b5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3571108991612603","idStr":"3571108991612603"},"htmlText":"BHC ever more than $100 few years back!","listText":"BHC ever more than $100 few years back!","text":"BHC ever more than $100 few years back!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118763550","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118700060,"gmtCreate":1622760211550,"gmtModify":1634098410137,"author":{"id":"3581993357014262","authorId":"3581993357014262","name":"Slee49","avatar":"https://static.tigerbbs.com/a4a9c556617a3ec3446f5c1c667b4aa0","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3581993357014262","idStr":"3581993357014262"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118700060","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118296600,"gmtCreate":1622732648500,"gmtModify":1634098585577,"author":{"id":"3582888287934264","authorId":"3582888287934264","name":"peterongwk","avatar":"https://static.tigerbbs.com/d59b7e35254008f12e8d269f053963b9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582888287934264","idStr":"3582888287934264"},"htmlText":"[Miser]&nbsp;[Surprised]&nbsp;","listText":"[Miser]&nbsp;[Surprised]&nbsp;","text":"[Miser] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/118296600","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4565865,"gmtCreate":1622732658826,"gmtModify":1635338375798,"authorId":3582888287934264,"author":{"id":3582888287934264,"idStr":"3582888287934264","authorId":3582888287934264,"name":"peterongwk","avatar":"https://static.tigerbbs.com/d59b7e35254008f12e8d269f053963b9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118296600,"type":1,"supId":0,"prevId":0,"content":"Up","text":"Up","html":"Up"},{"id":4568878,"gmtCreate":1622760842552,"gmtModify":1635338155790,"authorId":3574743613224710,"author":{"id":3574743613224710,"idStr":"3574743613224710","authorId":3574743613224710,"name":"RC_ADRIC","avatar":"https://static.tigerbbs.com/ff53482947c23ec372fe52411816b015","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118296600,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":118657811,"gmtCreate":1622731464633,"gmtModify":1634098606158,"author":{"id":"3582798351383607","authorId":"3582798351383607","name":"AHang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582798351383607","idStr":"3582798351383607"},"htmlText":"Gd","listText":"Gd","text":"Gd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118657811","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118686781,"gmtCreate":1622730410643,"gmtModify":1634098626933,"author":{"id":"3581571807225162","authorId":"3581571807225162","name":"Anneater","avatar":"https://static.tigerbbs.com/dd99ef969b35027be1194d21c5482e54","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3581571807225162","idStr":"3581571807225162"},"htmlText":"Pls like and comment thanks","listText":"Pls like and comment thanks","text":"Pls like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118686781","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4565258,"gmtCreate":1622730626554,"gmtModify":1635338415157,"authorId":3581571807225162,"author":{"id":3581571807225162,"idStr":"3581571807225162","authorId":3581571807225162,"name":"Anneater","avatar":"https://static.tigerbbs.com/dd99ef969b35027be1194d21c5482e54","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118686781,"type":1,"supId":0,"prevId":0,"content":"Oh","text":"Oh","html":"Oh"}],"langContent":"EN"},{"id":118611038,"gmtCreate":1622730039724,"gmtModify":1634098634942,"author":{"id":"3575629945584188","authorId":"3575629945584188","name":"RajaV","avatar":"https://static.tigerbbs.com/20786a1463560145b8b91408511f7b45","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3575629945584188","idStr":"3575629945584188"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118611038","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118694241,"gmtCreate":1622729626383,"gmtModify":1634098642942,"author":{"id":"3582369805071814","authorId":"3582369805071814","name":"TomTam","avatar":"https://static.tigerbbs.com/7d4158fab24080ff09635bb981677bf6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582369805071814","idStr":"3582369805071814"},"htmlText":"Like and comment pls&nbsp;","listText":"Like and comment pls&nbsp;","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118694241","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4565196,"gmtCreate":1622730395230,"gmtModify":1635338418562,"authorId":3581571807225162,"author":{"id":3581571807225162,"idStr":"3581571807225162","authorId":3581571807225162,"name":"Anneater","avatar":"https://static.tigerbbs.com/dd99ef969b35027be1194d21c5482e54","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118694241,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":118695495,"gmtCreate":1622729609217,"gmtModify":1634098643534,"author":{"id":"3584936349470741","authorId":"3584936349470741","name":"liwai100","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3584936349470741","idStr":"3584936349470741"},"htmlText":"Follow&nbsp;","listText":"Follow&nbsp;","text":"Follow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118695495","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118604097,"gmtCreate":1622729414919,"gmtModify":1634098650652,"author":{"id":"3560250280642807","authorId":"3560250280642807","name":"Flyinng","avatar":"https://static.tigerbbs.com/6e69ec197c553ae05464e21cec43ff61","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3560250280642807","idStr":"3560250280642807"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118604097","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4564828,"gmtCreate":1622729445701,"gmtModify":1635338444908,"authorId":3574809268346931,"author":{"id":3574809268346931,"idStr":"3574809268346931","authorId":3574809268346931,"name":"WeiKeong","avatar":"https://static.tigerbbs.com/5495c1f2e5e2d6067ea4add6d0b105c5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118604097,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"EN"},{"id":118603633,"gmtCreate":1622729279922,"gmtModify":1631891857752,"author":{"id":"3575374466628873","authorId":"3575374466628873","name":"Nairda","avatar":"https://static.tigerbbs.com/bc3f7836e992e3d289ce0aa35bb1f556","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575374466628873","idStr":"3575374466628873"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118603633","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4564831,"gmtCreate":1622729455034,"gmtModify":1635338444663,"authorId":3574809268346931,"author":{"id":3574809268346931,"idStr":"3574809268346931","authorId":3574809268346931,"name":"WeiKeong","avatar":"https://static.tigerbbs.com/5495c1f2e5e2d6067ea4add6d0b105c5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118603633,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"EN"},{"id":118600847,"gmtCreate":1622729214289,"gmtModify":1634098655409,"author":{"id":"3577178099298017","authorId":"3577178099298017","name":"DragonKC","avatar":"https://static.tigerbbs.com/f90c63c67a4e5f91e9dc0159f5b853ab","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3577178099298017","idStr":"3577178099298017"},"htmlText":"Going shopping for bargain stock.&nbsp;","listText":"Going shopping for bargain stock.&nbsp;","text":"Going shopping for bargain stock.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118600847","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118874310,"gmtCreate":1622729156930,"gmtModify":1634098657047,"author":{"id":"3568349626879479","authorId":"3568349626879479","name":"Alice156","avatar":"https://static.tigerbbs.com/60ff94c21a2d26f4682ac8ed41af2e37","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3568349626879479","idStr":"3568349626879479"},"htmlText":"Please like and&nbsp;comments","listText":"Please like and&nbsp;comments","text":"Please like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118874310","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4565694,"gmtCreate":1622732137442,"gmtModify":1635338387214,"authorId":3559956093286560,"author":{"id":3559956093286560,"idStr":"3559956093286560","authorId":3559956093286560,"name":"Jittertude","avatar":"https://static.tigerbbs.com/c657e13d97fc390ac319b8592838950e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118874310,"type":1,"supId":0,"prevId":0,"content":"pls like my comment too. Thanks","text":"pls like my comment too. Thanks","html":"pls like my comment too. Thanks"}],"langContent":"EN"},{"id":118845957,"gmtCreate":1622728901679,"gmtModify":1634098663879,"author":{"id":"3580342534451795","authorId":"3580342534451795","name":"Ultraviolet","avatar":"https://static.tigerbbs.com/0a37729d59392a2fd9ac9c4dbe50e826","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3580342534451795","idStr":"3580342534451795"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118845957","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118846130,"gmtCreate":1622728832320,"gmtModify":1634098664454,"author":{"id":"3576319038001885","authorId":"3576319038001885","name":"Natdns","avatar":"https://static.tigerbbs.com/be6cb184b10d5e613602b38d396409cf","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3576319038001885","idStr":"3576319038001885"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118846130","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4564687,"gmtCreate":1622728950044,"gmtModify":1635338454289,"authorId":3580342534451795,"author":{"id":3580342534451795,"idStr":"3580342534451795","authorId":3580342534451795,"name":"Ultraviolet","avatar":"https://static.tigerbbs.com/0a37729d59392a2fd9ac9c4dbe50e826","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118846130,"type":1,"supId":0,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"langContent":"EN"},{"id":118861338,"gmtCreate":1622728148924,"gmtModify":1634098681110,"author":{"id":"3566032787349185","authorId":"3566032787349185","name":"Khoogl","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3566032787349185","idStr":"3566032787349185"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118861338","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118884455,"gmtCreate":1622728051477,"gmtModify":1634098684195,"author":{"id":"3572305441240915","authorId":"3572305441240915","name":"LongZR","avatar":"https://static.tigerbbs.com/80b6c7bb6866455f69d500fddb520c7e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3572305441240915","idStr":"3572305441240915"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118884455","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4564372,"gmtCreate":1622728061322,"gmtModify":1635338474292,"authorId":3572305441240915,"author":{"id":3572305441240915,"idStr":"3572305441240915","authorId":3572305441240915,"name":"LongZR","avatar":"https://static.tigerbbs.com/80b6c7bb6866455f69d500fddb520c7e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118884455,"type":1,"supId":0,"prevId":0,"content":"like and <u>like</u>","text":"like and <u>like</u>","html":"like and <u>like</u>"}],"langContent":"EN"},{"id":118886125,"gmtCreate":1622727981667,"gmtModify":1634098686301,"author":{"id":"3576717801191675","authorId":"3576717801191675","name":"labide","avatar":"https://static.tigerbbs.com/367084595c376dc0587e9cbcd9735b48","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3576717801191675","idStr":"3576717801191675"},"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118886125","repostId":2140476423,"repostType":4,"repost":{"id":"2140476423","pubTimestamp":1622727648,"share":"https://www.laohu8.com/m/news/2140476423?lang=&edition=full","pubTime":"2021-06-03 21:40","market":"us","language":"en","title":"The 3 Best Stocks to Buy for Summer 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2140476423","media":"Motley Fool","summary":"Looking for huge winners over the long run? Here are three top picks.","content":"<p>Over the past year, the <b>S&amp;P 500</b>&nbsp;benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.&nbsp;</p>\n<p>Three high-flying stocks at a reasonable price are&nbsp;<b>Bumble</b>&nbsp;(NASDAQ:BMBL),&nbsp;<b>Beyond Meat</b>&nbsp;(NASDAQ:BYND), and&nbsp;<b>Bausch Health Companies&nbsp;</b>(NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e382e7e2d41e4db616c7b79cf3e2e38d\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bumble&nbsp;</h2>\n<p>Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. </p>\n<p>During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.</p>\n<p>Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.&nbsp;</p>\n<h2>2. Beyond Meat</h2>\n<p>Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.&nbsp;</p>\n<p>For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. </p>\n<p>The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. </p>\n<p>The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.&nbsp;</p>\n<h2>3. Bausch Health Companies&nbsp;</h2>\n<p>Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. </p>\n<p>The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. </p>\n<p>Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment.&nbsp;<i>Bloomberg</i> estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. </p>\n<p>If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. </p>\n<p>Right now, Bausch Health Companies is <a href=\"https://laohu8.com/S/AONE\">one</a> of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Stocks to Buy for Summer 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Stocks to Buy for Summer 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BHC":"Bausch Health Companies Inc","BMBL":"Bumble Inc."},"source_url":"https://www.fool.com/investing/2021/06/03/3-best-stocks-to-buy-for-summer-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140476423","content_text":"Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely. \nThree high-flying stocks at a reasonable price are Bumble (NASDAQ:BMBL), Beyond Meat (NASDAQ:BYND), and Bausch Health Companies (NYSE:BHC). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively. \nImage source: Getty Images.\n1. Bumble \nBumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users. \nDuring the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.\nMoving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider. \n2. Beyond Meat\nBeyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach. \nFor starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to \"meat\" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment. \nThe company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019. \nThe stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now. \n3. Bausch Health Companies \nBausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA. \nThe company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone. \nFortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion. \nIf the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products. \nRight now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":44,"commentSize":17,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}